Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results

TitleRandomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results
Publication TypeJournal Article
Year of Publication2000
AuthorsPiccart, MJ, Bertelsen, K, James, K, Cassidy, J, Mangioni, C, Simonsen, E, Stuart, GCE, Kaye, SB, Vergote, IB, Blom, R, Grimshaw, R, Atkinson, RJ, Swenerton, KD, Tropé, CG, Nardi, M, Kaern, J, Tumolo, S, Timmers, P, Roy, J-A, Lhoas, F, Lindvall, B, Bacon, M, Birt, A, Andersen, JE, Zee, B, Paul, J, Baron, B, Pecorelli, S
JournalJ Natl Cancer Inst
Volume92
Pagination699-708
Keywords80 and over Alopecia/chemically induced Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use Cisplatin/administration & dosage/adverse effects Combined Modality Therapy Cross-Over Studies Cyclophosphamide/administration & dosag, Adult Aged Aged
Abstract

BACKGROUND: A randomized trial conducted by the Gynecologic Oncology Group (GOG, study #111) in the United States showed a better outcome for patients with advanced ovarian cancer on the paclitaxel-cisplatin regimen than for those on a standard cyclophosphamide-cisplatin regimen. Before considering the paclitaxel-cisplatin regimen as the new "standard," a group of European and Canadian investigators planned a confirmatory phase III trial. METHODS: This intergroup trial recruited 680 patients with broader selection criteria than the GOG #111 study and administered paclitaxel as a 3-hour instead of a 24-hour infusion; progression-free survival was the primary end point. Patient survival was analyzed by use of the Kaplan-Meier technique. Treatment effects on patient survival were estimated by Cox proportional hazards regression models. All statistical tests were two-sided. RESULTS: The overall clinical response rate was 59% in the paclitaxel group and 45% in the cyclophosphamide group; the complete clinical remission rates were 41% and 27%, respectively; both differences were statistically significant (P =.01 for both). At a median follow-up of 38.5 months and despite a high rate of crossover (48%) from the cyclophosphamide arm to the paclitaxel arm at first detection of progression of disease, a longer progression-free survival (log-rank P =.0005; median of 15.5 months versus 11.5 months) and a longer overall survival (log-rank P =. 0016; median of 35.6 months versus 25.8 months) were seen in the paclitaxel regimen compared with the cyclophosphamide regimen. CONCLUSIONS: There is strong and confirmatory evidence from two large randomized phase III trials to support paclitaxel-cisplatin as the new standard regimen for treatment of patients with advanced ovarian cancer.